Noninvasive near-infrared blood glucose monitoring using a calibration model built by a numerical simulation method: Trial application to patients in an intensive care unit

被引:37
作者
Maruo, Katsuhiko [1 ]
Oota, Tomohiro
Tsurugi, Mitsuhiro
Nakagawa, Takehiro
Arimoto, Hidenobu
Hayakawa, Mineji
Tamura, Mamoru
Ozaki, Yukihiro
Yamada, Yukio
机构
[1] Matsushita Elect Ind Co Ltd, Kadoma, Osaka 5718686, Japan
[2] Natl Inst Adv Ind Sci & Technol, Tsukuba, Ibaraki 3058564, Japan
[3] Hokkaido Univ Hosp, ICU, Sapporo, Hokkaido 0608648, Japan
[4] Hokkaido Univ, Div Cellular Life Sci, Sapporo, Hokkaido 0600812, Japan
[5] Kwansei Gakuin Univ, Sch Sci & Technol, Dept Chem, Sanda 6691337, Japan
[6] Kwansei Gakuin Univ, Sch Sci & Technol, Res Ctr Near Infrared Spect, Sanda 6691337, Japan
[7] Univ Electrocommun, Dept Mech Engn & Intelligent Syst, Chofu, Tokyo 1828585, Japan
关键词
D O I
10.1366/000370206779321508
中图分类号
TH7 [仪器、仪表];
学科分类号
0804 ; 080401 ; 081102 ;
摘要
We have applied a new methodology for noninvasive continuous blood glucose monitoring, proposed in our previous paper, to patients in ICU (intensive care unit), where strict controls of blood glucose levels are required. The new methodology can build calibration models essentially from numerical simulation, while the conventional methodology requires pre-experiments such as sugar tolerance tests, which are impossible to perform on ICU patients in most cases. The in vivo experiments in this study consisted of two stages, the first stage conducted on healthy subjects as preliminary experiments, and the second stage on ICU patients. The prediction performance of the first stage was obtained as a correlation coefficient (r) of 0.71 and standard error of prediction (SEP) of 28.7 mg/dL. Of the 323 total data, 71.5% were in the A zone, 28.5% were in the B zone, and none were in the C, D, and E zones for the Clarke error-grid analysis. The prediction performance of the second stage was obtained as an r of 0.97 and SEP of 27.2 mg/dL. Of the 304 total data, 80.3% were in the A zone, 19.7% were in the B zone, and none were in the C, D, and E zones. These prediction results suggest that the new methodology has the potential to realize a noninvasive blood glucose monitoring system using near-infrared spectroscopy (LAIRS) in ICUs. Although the total performance of the present monitoring system has not yet reached a satisfactory level as a stand-alone system, it can be developed as a complementary system to the conventional one used in ICUs for routine blood glucose management, which checks the blood glucose levels of patients every few hours.
引用
收藏
页码:1423 / 1431
页数:9
相关论文
共 23 条
[1]   Phantom glucose calibration models from simulated noninvasive human near-infrared spectra [J].
Arnold, MA ;
Burmeister, JJ ;
Small, GW .
ANALYTICAL CHEMISTRY, 1998, 70 (09) :1773-1781
[2]   Closed-loop glucose control in critically ill patients using continuous glucose monitoring system (CGMS) in real time [J].
Chee, F ;
Fernando, T ;
van Heerden, PV .
IEEE TRANSACTIONS ON INFORMATION TECHNOLOGY IN BIOMEDICINE, 2003, 7 (01) :43-53
[3]   Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock [J].
Dellinger, RP ;
Carlet, JM ;
Masur, H ;
Gerlach, H ;
Calandra, T ;
Cohen, J ;
Gea-Banacloche, J ;
Keh, D ;
Marshall, JC ;
Parker, MM ;
Ramsay, G ;
Zimmerman, JL ;
Vincent, JL ;
Levy, MM .
CRITICAL CARE MEDICINE, 2004, 32 (03) :858-873
[4]  
Goldberg Philip A, 2004, Diabetes Technol Ther, V6, P339, DOI 10.1089/152091504774198034
[5]  
Heise HM, 2002, NEAR-INFRARED SPECTROSCOPY: PRINCIPLES, INSTRUMENTS, APPLICATIONS, P289
[6]  
Heise HM, 1998, JOURNAL OF NEAR INFRARED SPECTROSCOPY, VOL 6 1998, P349
[7]  
HEISE HM, 1997, BIOSENSORS BODY CONT, P79
[8]   Monte Carlo simulation of near infrared reflectance spectroscopy in the wavelength range from 1000 nm to 1900 nm [J].
Iino, K ;
Maruo, K ;
Arimoto, H ;
Hyodo, K ;
Nakatani, T ;
Yamada, Y .
OPTICAL REVIEW, 2003, 10 (06) :600-606
[9]  
Kawano S, 2002, NEAR-INFRARED SPECTROSCOPY: PRINCIPLES, INSTRUMENTS, APPLICATIONS, P115
[10]  
Koschinsky Theodor, 2003, Diabetes Technol Ther, V5, P829, DOI 10.1089/152091503322527030